期刊文献+

前列腺素E_1治疗糖尿病肢端坏疽疗效观察

Prostaglandin E_1 for treating foot gangrene in diabetic patients
在线阅读 下载PDF
导出
摘要 目的 探讨前列腺素E1对糖尿病肢端坏疽的治疗效果。方法自2004年6月-2006年2月对58例患者,采取随机分组,治疗组30例用前列腺素E1加基础治疗方法,对照组28例用复方丹参加基础治疗,观察84d。结果治疗组溃疡总有效率90%,疼痛总有效率83%,观察组溃疡总有效率60%,疼痛总有效率57%,治疗前后两组患者的股动脉、腘动脉及足背动脉内径和血流量差异均有统计学意义(P〈0.05)。结论前列腺素E1是治疗糖尿病肢端坏疽的有效药物。 Objective To probe the effect of prostaglandin E1 (PGE1) in treating diabetic foot gangrene. Methods Fifty-eight patients were selected and divided into 2 groups randomly from Jun. 2004 to Feb. 2006. Then the 30 patients in the experimental group were treated with prostaglandin E1 adding basic therapy, while 28 patients in control group were treated with compound dansen for 84 days. Results In experimental group, the total curative rate of foot ulcer was 90% and the total curative rate of the pain was 83% ,while in control group the'total curative rate of foot ulcer was 60% and the pain was 57%. There curative were significant differences( P 〈 0.05) in inner diameter and the blood flow in the femoral artery,popliteal artery and dorsal pedal before and after treatment in two groups. Conclusion Prostaglandin E1 is an effective drug for treating diabetic foot gangrene.
作者 宋瑞捧 袁群
出处 《中原医刊》 2006年第10期16-17,共2页 Central Plains Medical Journal
关键词 前列腺素E1 糖尿病肢端坏疽 Prostaglandin E1 Diabetic foot gangrene
  • 相关文献

参考文献2

二级参考文献13

  • 1刘嵋,张金辉.糖尿病性神经病变的药物治疗现状[J].中华内分泌代谢杂志,1996,12(1):37-39. 被引量:193
  • 2[1]Greene DA,Sima AAF,Stevens MJ,et al.Complications:Neuropathy Pathogenetic considerations.Diabetes Care,1992,15 (1):1902-1903.
  • 3[5]Flynm MD,Tooke JE.Diabetic nearopathy and the microcirculation.Diabet Med,1995,12 (12):298-299.
  • 4Cawello W,Leonhardt A,Schweer H,etal.Dose proportional pharmacokinetics of alpro-stadil (prostaglandin E1)in healthyvolunteers following intravenous infusion 〔J〕.Br J Clin Pharmacol,1995,40:273~276.
  • 5Anggard E.The biological activities of three metabolites of prostaglandin E1 〔J〕.ActaPhysiol Scand,1996,66:509~510.
  • 6Yasuda H,Maeda K,Sonobe M,et al.Metabolic effect of PGE1 analogue O1206.αCD onnerve Na+-K+-ATPase activity of rats with streptozotocin-induced diabetes is mediatedvia cAMP: possible role of cAMP in diabetic neuropathy 〔J〕.Prostaglandins,1994,47:367~378.
  • 7Okada S,Ichiki K,Tanokuchi S,et al.Effect of prostaglandin E1 on therenin-aldosterone system in patients with diabetic nephropathy 〔J〕.J Int MedRes,1993,21:126~132.
  • 8Young MJ, Veves A,Smith JV, et al.Restoring lower limb blood flow improvesconduction velocity in diabetic patients 〔J〕.Diabetologia,1995,38:1051~1054.
  • 9Partanen J,Niskanen L,Lehtinen J,et al.Natural history of peripheral neuropathy inpatients with non-insulin-dependent diabetes mellitus 〔J〕. N Engl J Med,1995,333:89~94.
  • 10Yasuda H,Sonobe M,Hatanaka I,et al.A new prostaglandin E1 analogue (TFC-612)prevents a decrease in motor conduction velocity in streptozocin-diabetic rats 〔J〕.BiochemBiophys Res Commun,1998,150:225~230.

共引文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部